Eribulin in Cancer Treatment

by Umang Swami, Umang Shah, Sanjay Goel
Published 2015-08-01

Harnessing DNA Replication Stress for Novel Cancer Therapy

by Huanbo Zhu, Umang Swami, Ranjan Preet, Jun Zhang
Published 2020-08-01

Clinical Challenges with Talimogene Laherparepvec: Cured Lymph Nodes Masquerading as Active Melanoma

by Umang Swami, Brian Swick, Yousef Zakharia, Mohammed Milhem
Published 2019-01-01

Immune Checkpoint Inhibitors in Prostate Cancer

by Shobi Venkatachalam, Taylor R. McFarland, Neeraj Agarwal, Umang Swami
Published 2021-05-01

Durable Clinical Benefit in Patients with Advanced Cutaneous Melanoma after Discontinuation of Anti-PD-1 Therapies Due to Immune-Related Adverse Events

by Umang Swami, Varun Monga, Aaron D. Bossler, Yousef Zakharia, Mohammed Milhem
Published 2019-01-01

A Phase I/II Study Targeting Angiogenesis Using Bevacizumab Combined with Chemotherapy and a Histone Deacetylase Inhibitor (Valproic Acid) in Advanced Sarcomas

by Varun Monga, Umang Swami, Munir Tanas, Aaron Bossler, Sarah L. Mott, Brian J. Smith, Mohammed Milhem
Published 2018-02-01

Multivariable Analysis of 169 Cases of Advanced Cutaneous Melanoma to Evaluate Antibiotic Exposure as Predictor of Survival to Anti-PD-1 Based Immunotherapies

by Umang Swami, Adithya Chennamadhavuni, Nicholas Borcherding, Aaron D. Bossler, Sarah L. Mott, Rohan Garje, Yousef Zakharia, Mohammed Milhem
Published 2020-10-01

Real-world experience with elective discontinuation of PD-1 inhibitors at 1 year in patients with metastatic melanoma

by Siwen Hu-Lieskovan, Rebecca Pokorny, Jordan P McPherson, Carolyn Luckett, Benjamin Newell Voorhies, Daniel S Sageser, Jocelyn Wallentine, Zachary Tolman, Umang Swami
Published 2021-01-01

Melanoma Brain Metastases in the Era of Targeted Therapy and Checkpoint Inhibitor Therapy

by John M. Rieth, Umang Swami, Sarah L. Mott, Mario Zanaty, Michael D. Henry, Aaron D. Bossler, Jeremy D. Greenlee, Yousef Zakharia, Marion Vanneste, Brooke Jennings, Mohammed M. Milhem
Published 2021-03-01